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I. Introduction 
 
 
Diabetes mellitus is a metabolic, non –communicable disease, 
characterized by chronic hyperglycemia with disturbance in the carbohydrate, 
protein and fat metabolism, resulting from defects in insulin secretion, insulin 
action or both (1). Diabetes continues to be a public health concern. The 
Incidence of Diabetes mellitus increases globally & national wide. It has been 
estimated that within 10 years nearly 380 million individuals would be affected 
by diabetes worldwide and in India alone 41 million individuals would be 
affected. (2,3). This will constitute nearly about 15% of the world’s burden. 
Effective preventive measures are therefore needed and modifiable risk factors 
should be identified and explored. Recent studies have shown a relationship 
between Vitamin-D - 1, 25 dihydroxy cholecalciferol and type 2 diabetes 
mellitus. 
 
Vitamin D is a hormone, synthesized in the skin on exposure to sunlight. 
It’s function is mainly related to skeletal integrity and it’s deficiency is 
associated with diseases such as rickets in children , osteomalacia in adults & 
osteoporosis . It also has extra skeletal effects like diabetes mellitus, 
hypertension , metabolic syndrome, atherosclerosis , myocardial infarction , 
and stroke. (4) .Vitamin D deficiency is one of the commonest disorder found 
in all the age groups. 
 
Hypovitaminosis D is widespread and it is reemerging as a major 
health concern globally. The prevalence of vitamin D deficiency in adults is 
about 20-30% (5). 
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 Inflammatory factors, reactive oxygen species and autoimmune 
reactions are the major pathogenic effectors for diabetes. Recently vitamin D 
has sparked widespread interest in pathogenesis of diabetes by playing a role 
 
in Insulin resistance. Type 2 Diabetes & Vitamin D deficiency have risk factors 
in common such as race, obesity, ageing & low physical activity. (8). 
 
Vitamin D receptors   has been identified in pancreatic islets and 
vitamin D dependent calcium binding protein  in  pancreatic tissue. (7) . As  a 
major  regulator of homeostasis of calcium,  Vitamin  D  directly and  or 
indirectly improves insulin exocytosis and glucose tolerance. (6).Vitamin D 
reduces  insulin resistance  through  its  effect  on  calcium  and  phosphorus 
metabolism and through upregulation of the insulin receptor  gene .(9). 
 
Glycated hemoglobin (HbA1C) is widely used in diagnosing diabetes 
mellitus and used as a global measure of assessing the glycemic control in 
diabetes. (10).Glycated hemoglobin can be interpreted as an average of blood 
glucose produced over the past 3-4 months . It is an integral component to 
asses the management of patients with diabetes, to monitor the long term 
glycemic control and as a measure of the risk for the development of diabetic 
complications. 
 
In diabetes Insulin deficiency leads to excessive mobilization of free 
fatty acids and underutilization of chylomicrons and VLDL , resulting in 
dyslipidemia. (12). Cholesterol level is increased by decreased conversion of 
cholesterol into bile acids.(11) 
 
In this study serum fasting and postprandial blood sugar , glycated 
hemoglobin and lipid profile were done to asses the glycemic control and lipid 
status to find its correlation with levels of Vitamin D in Diabetes mellitus 
patients. 
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 II. REVIEW OF LITERATURE 
 
 
Diabetes is a metabolic disease that affects nearly every organ system in 
the body, characterized by polyuria , polyphagia , polydypsia , weight loss and 
muscle wasting , leading on to micro and macro vascular complications like 
myocardial infarction , stroke , retinopathy, peripheral neuropathy and 
nephropathy. (13). In addition hypertension secondary to renal injury and 
atherosclerosis secondary to abnormal lipid metabolism develops in patients 
with diabetes. 
 
Diabetes was first recognized by Ancient Egyptians . Mering and 
Minowski of ASTRIA explained the role of pancreas in the pathogenesis of 
diabetes in 1889. Banting and Best of CANADA were awarded Nobel prize in 
1923 for isolation and clinical use of Insulin. 
 
EPIDEMIOLOGY 
 
Diabetes is a growing  public health problem throughout  the world. 
 
Global prevalence 
 
According to the WHO statement nearly 180 million people worldwide 
 
have diabetes .The prevalence of Diabetes worldwide will be 4.4% in 2030 . 
 
[14]. Global mortality associated with diabetes is nearly four million deaths 
 
in 2010, which accounts for 6.8% of  the global  cause. [IDF – 2009 Report]. 
 
Indian Prevalence 
 
In India the increase of burden of Diabetes is estimated to be 58%, from 
51 million people in 2010 to 87 million in 2030. (15). According to World 
Health Organization criteria , the prevalence of known diabetes was 5.6% and 
2.7% among urban and rural areas.(17) 
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 The impact of type 2 Diabetes mellitus is to increase mortality and 
morbidity and to decrease the quality of life .(16). Diabetes and its 
complication cause a heavy economic burden for the patient themselves , their 
families and to the society. The prevalence of Diabetes is higher in men than 
women. (18). 
 
Several distinct types of diabetes mellitus exist and are caused by a 
complex interaction of genetic and environmental factors . The metabolic 
dysregulation associated with Diabetes mellitus causes secondary 
pathophysiologic changes in multiple organ systems, that impose a tremendous 
burden on the individual with diabetes and on the health care system. (19). 
 
Classification: 
 
 
Diabetes mellitus is classified on the basis of the pathogenic process 
that leads to hyperglycemia. 
 
The classification of diabetes includes four clinical classes. (20). 
 
 
1. Type I Diabetes mellitus 
 
 
2. Type 2 Diabetes mellitus 
 
 
3. Other specific type of diabetes due to various other causes 
 
 
4. Gestational diabetes mellitus (GDM) 
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 Type 1 Diabetes 
 
Type I Diabetes is primarily due to Beta cell destruction .This usually 
leads to a type of diabetes in which insulin is required for survival. (21) . It is 
also referred to as insulin – dependent diabetes mellitus (IDDM) and Juvenile 
diabetes. (22) .Type I Diabetes is further classified as (a) immune mediated 
diabetes and (b) Idiopathic diabetes . 
 
A. Immune mediated diabetes 
 
Immune mediated diabetes account for only 5-10% of diabetes . It 
commonly occurs in childhood and adolescence , but it can occur at any age. It 
results from a cellular mediated autoimmune destruction of the Beta-cells of 
the pancreas. Circulating antibodies against insulin is seen in 50% cases. 
 
B. Idiopathic diabetes 
 
The patient many have permanent hyperinsulinemia and are prone to 
ketoacidosis, but have no evidence of autoimmunity. This form of diabetes is 
strongly inherited, lacks immunological evidence for beta cell autoimmunity 
and is not HLA associated . 
 
Type 2 Diabetes Mellitus 
 
Type 2 Diabetes results form a progressive insulin secretory defect on 
the background of Insulin resistance . (23) .Type 2 Diabetes mellitus accounts 
for 90-95% of those with Diabetes . Previously it is referred to as non-insulin 
dependent diabetes , type 2 Diabetes , or adult onset diabetes , and it 
encompasses individuals who have insulin resistance and relative insulin 
deficiency. This form of diabetes is associated with progressive beta cell failure 
with increasing duration of diabetes .(24). 
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 RISK FACTORS FOR DIABETES MELLITUS 
 
The known risk factors for type 2 Diabetes mellitus are as follows 
 
 
I. Modifiable Risk factors 
 
1. Obesity 
 
2. Physical inactivity 
 
3. Hypertension 
 
4. Dyslipidemia 
 
5. Diet 
 
II. Non- Modifiable Risk factors 
 
1. Family history 
 
2. Genetic factors 
 
 
The risk of developing Type 2 Diabetes mellitus is mainly determined 
by both genetic and environmental factors. 
 
i. Genetic Consideration of Type 2 Diabetes mellitus 
 
 
The genetic component constitutes the development of diabetes between 
relatives of patients with Type 2 diabetes mellitus and the background 
population . If one parent have Type 2 Diabetes mellitus than the life time risk 
of developing Type 2 Diabetes mellitus in offspring is 40% and if both parents 
are affected the risk is almost 70%. The genes that predispose to type 2 
Diabetes mellitus are incompletely identified and investigation using genome 
 
– wide scanning for polymorphisms associated with type 2 Diabetes mellitus  is 
 
ongoing .(25). 
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 ii. Environmental factors, such as diet and exercise are  important  in  the 
 
determination of the pathogenesis of non insulin dependent diabetes mellitus . 
An inverse relationship exists between the level of physical activity and the 
prevalence of non insulin dependent diabetes mellitus. 
 
Pathophysiology of Type 2 Diabetes Mellitus 
 
 
Insulin is produced constantly within the beta cells of pancreas irrespective 
of blood glucose levels. It is stored within the vacuoles and released by 
exocytosis, which is primarily triggered by food containing absorbable glucose. 
So, the chief triggering factor for rise in blood glucose level is food. (26) 
 
Type 2 Diabetes mellitus is characterized by impaired insulin secretion, 
insulin resistance, excessive hepatic production of glucose and abnormal fat 
metabolism. 
 
Insulin resistance 
 
 
Insulin resistance is defined as a decreased biological response to 
normal concentration of circulating insulin. It is usually attributed to a defect in 
insulin action. 
 
Loss of beta cell function 
 
 
The increased beta cell secretion of insulin induced by insulin resistance 
is associated with progressive loss of beta cell function that is necessary for the 
development of fasting hyperglycemia . The major defect is the loss of glucose 
induced insulin release which is termed as selective glucose unresponsiveness . 
And also there is an abnormality in normal pulsatile release of insulin and 
increased ratio of plasma proinsulin to insulin. 
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 In the early stages of the disorder glucose tolerance remains near - 
normal despite insulin resistance, because of the compensation of pancreatic 
beta cells by increasing insulin output . As insulin resistance and compensatory 
hyperinsulinemia progress, the pancreatic islets in some individuals are unable 
 
to sustain the hyperinsulinemic state. Impaired glucose tolerance characterized 
by elevations in postprandial glucose develops later. A further decline in 
 
insulin secretion and increase in hepatic glucose production leads to overt 
diabetes with fasting hyperglycemia and ultimately, beta cell failure may 
ensure. 
 
Other Specific types of diabetes 
 
 
Other specific types of Diabetes are caused by the body’s tissue 
receptors not responding to insulin, even though the levels of insulin is normal. 
Genetic mutations can also lead to defects in the beta cell function and 
abnormal insulin action . Diseases which may extensively damage the pancreas 
like chronic pancreatitis and cystic fibrosis may lead to diabetes. Excessive 
secretion of insulin – antagonistic hormones can cause diabetes. 
 
Comprehensive list of other specific types of diabetes. (27) 
 
A .Genetic defects in beta cell function 
 
Chromosome 12, HNF – 1 alpha (MODY 3) 
 
Chromosome 7, glucokinase (MODY 2) 
 
Chromosome 20, HNF – 4 alpha (MODY 1) 
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 B. Genetic defects in insulin action 
 
1. Type A insulin resistance 
 
2. Leprechaunism 
 
3. Rabson – Mendenhall syndrome 
 
4. Lipoatrophic diabetes 
 
C. Diseases of Exocrine pancreas 
 
 
D. Endocrinopathies 
 
E. Drug or  Chemical Induced 
 
F. Infections 
 
G. Immune-mediated , uncommon forms 
 
H. Other Genetic Syndromes sometimes associated with diabetes. 
 
 
Gestational Diabetes mellitus (GDM) 
 
Gestational diabetes mellitus is glucose intolerance  with the  onset  of 
 
pregnancy or first recognition during pregnancy. (28). Gestational diabetes 
 
affects nearly 5% of  all pregnancies and its incidence is increasing (29)  . 
 
Women with gestational diabetes mellitus are at a greater risk of developing 
 
type 2 Diabetes mellitus within 10-20 years of their index pregnancy 
(30).Babies of GDM mother are also at high risk of developing diabetes at their 
later age. Gestational diabetes mellitus is due to the inability of pancreatic Beta 
cells to release the insulin to compensate the pregnancy induced insulin 
resistance, resulting in maternal hyperglycemia and hyperinsulinemia . (31). 
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 Diagnostic Criteria for type 2 diabetes mellitus. 
 
 
International expert committee with members of American Diabetes 
Association, The European Association of Diabetes and The International 
Diabetes Federation has issued the diagnostic criteria for diabetes.(32). 
 
Diabetes mellitus is characterized by recurrent or persistent 
hyperglycemia, and is diagnosed by demonstration of any one of the following, 
 
 
Glycated  hemoglobin (HbA1C)  ≥ 6.5% (48 mmol/m1) 
 
 
Fasting plasma glucose level 
caloric intake for atleast 8 hrs 
 
 
≥ 7.0 mmol (≥ 126 mg/dl) – with no 
 
Plasma glucose ≥ 11.1 mmol//L (≥200mg/dl) 2 hours after a 75g oral 
glucose load as in a glucose tolerance test 
 
Symptoms of hyperglycemia and random plasma glucose ≥11.1mmol/L 
(200 mg/dl) 
 
A positive result , in the absence of unequivocal hyperglycemia should 
be confirmed by a repeat of any one of the above- listed test on a different day. 
Fasting plasma glucose is the preferred test for diagnosis of diabetes. 
 
Metabolic abnormalities in Diabetes 
 
 
Derangement in carbohydrate metabolism: Insulin deficiency 
decreases the uptake of glucose by cells .The insulin dependent enzymes are 
 
less active, there by inhibition of glycolysis and stimulation of gluconeogenesis 
occurs, leading to hyperglycemia. 
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 Derangement in protein metabolism: Increased breakdown of proteins 
and amino acids occur to provide substrate for gluconeogenesis,which is 
responsible for muscle wasting in Diabetes. 
 
Derangement in lipid metabolism: 
 
 
a. increased fatty acid breakdown leads to high free fatty acid levels 
of plasma , leading to increased lipid synthesis in liver 
hepatocytes . 
 
b. The stimulation of gluconeogenesis is responsible for the 
oxaloacetate depletion. A available more acetyl CoA is oxidized 
by TCA cycle , because of limited availability of oxaloacetate . 
 
c. The excess of acetyl COA is  diverted to  ketone body synthesis, 
 
leading to ketogenesis . There is hyperlipidemia, especially an 
 
increase in NEFA , triacylglycerol and cholesterol in plasma . 
 
Excess of acetyl CoA is also used for cholesterol synthesis. 
 
 
Complications of Diabetes mellitus.(33) 
 
 
A. Acute metabolic complications 
Diabetic Ketoacidosis 
 
Hyper osmolar nonketotic coma 
Lactic acidosis 
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 B. Chronic Complications of Diabetes 
 
i.Microvascular  complications 
 
a. Eye Diseases 
 
Retinopathy, Macular |Edema 
 
b. Neuropathy 
 
 
Sensory and motor, Autonomic 
 
 
c. Nephropathy 
 
 
ii.Macrovascular complications 
 
 
a. Coronary artery disease 
 
 
b. Peripheral arterial disease 
 
 
c. Cerebrovascular disease 
 
 
C.Other complications 
 
 
a. Gastrointestinal 
 
 
b. Gentiourinary 
 
 
c. Dermatologic 
 
 
d. Infections 
 
 
e. Cataract 
 
 
f. Glaucoma 
 
 
g. Periodontal disease 
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 Vitamin D 
 
 
Vitamin D was first identified in 1923 by Goldblatt and Soames . 
Windows a German chemist found the structure of vitamin D2 and D3 in 1928. 
(34). De Luca, Fraser and Norman established vitamin D as a prohormone, 
which is converted to its active form by successive hydroxylation at 25 and 1 – 
position. 
 
Epidemiology 
 
 
Vitamin D deficiency is widespread in different parts of the world , with 
an increased incidence in high and low latitude countries . The prevalence of 
vitamin D deficiency is 33% according to The National Health and Nutrition 
Examination Survey. The prevalence of hypovitaminosis D in south India is 
40% in males and 70% in females. 
 
The lifestyle changes like more indoor activity , use of sunscreens , 
obesity can favour vitamin D deficiency. 
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Biosynthesis of Vitamin D 
 
Vitamin D  exist  in 2 forms , vitamin D2 and vitamin D3. 
 
1. Vitamin D2 or ergocalciferol is derived from erogosterol 
 
 
2. Vitamin D3 or Cholecalciferol is synthesized in the skin from 7 
dehydro cholesterol via photochemical synthesis using UltraViolet- B 
rays (290 to 310nm) from sunlight to form Pre-vitamin D3 . 
 
The resultant pre-vitamin D3 is thermally labile . It undergoes 
temperature dependent non-enzymatic molecular rearrangement over a 
period of 48 hours to form Vitamin D3.The excessive amount of 
 
Vitamin D production on prolonged sun exposure is prevented by 
isomerization to biologically inert products like luminosterol and 
tachysterol .(35).The Difference between vitamin D2 and vitamin D3 is 
the presence of double bond between C22 and C23 and methyl group in 
C24 side chain .(36). 
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METABOLISM OF VITAMIN-D 
 
 
 
 
 
 
 
 
 
 
 
Sources of Vitamin D 
 
 Sunlight .


 Natural sources like cod liver oil, fish, egg yolk, fortified 
foods like milk, yogurts, butter & cheese.
 
Metabolism of Vitamin D 
 
 
Vitamin D by itself has no hormonal activity. It undergoes two 
sequential hydroxylation , in the liver at 25
th
 carbon and in the kidney at 1
st
 
carbon to become biologically active form 1,25 dihydroxycholecalciferol. 
 
25 & 1 alpha hydroxylation 
 
 
In the liver vitamin D is hydroxylated at carbon 25 to 25 hydroxy 
 
vitamin D  by  25  hydroxylase enzyme . In kidneys 25  hydroxy vitamin D 
 
is converted to an activated 1, 25 dihydroxy vitamin D , by 1 alpha hydroxylase 
enzyme, which is a biologically active form of vitamin D. The factors 
regulating the production of 1, 25 (OH ) 2 D3 in kidneys are levels of 
parathyroid hormone and 1 alpha hydroxylase. 
 
Vitamin D is bound with vitamin D binding protein (DBP) in 
circulation.(37). 
 
The major route of excretion of vitamin D is through the bile . Calcitroic 
acid which is the final degradation product of 24 hydroxylase pathway , is 
excreted in urine. 
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 Biochemical effects of Vitamin D 
 
1 , 25 dihydroxycholecalciferol mediates its biological effects by binding to 
a member of the nuclear receptor super family, the vitamin D receptors 
 
(VDR) .This receptor belongs to the subfamily that also includes the retinoid 
receptors, thyroid hormone receptors and  the peroxisome  proliferator – 
activated receptors. The  VDR  binds  to target DNA sequences   as a 
 
heterodimer with the retinoid X receptor, recruiting a series of coactivators , 
that modify chromatin and result in the induction of target gene expression. 
(38). 
 
Functions of Vitamin D: 
 
Vitamin D plays an important role in calcium homeostasis. The calcium 
homeostasis is regulated by its endocrine function and its non-calcitropic 
effects such as cellular differentiation and replication in many organs via its 
paracrine and autocrine role .(39). 
 
The virtual expression of VDR in all nucleated cells , and the presence 
of 1 alpha hydroxylase in different tissues like heart , brain , stomach , gonads , 
skin , pancreas , colon , placenta , immune system and vascular endothelium , a 
part from kidney , relates the role of vitamin D as a hormone and in immune 
function.(40,41) 
 
1. Vitamin D has a protective role in cancer by reducing cell proliferation 
and promoting cell differentiation. 
 
2. Protection in development of atherosclerosis by VDR present in 
vascular endothelial smooth muscle cells which inhibit macrophage 
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 cholesterol uptake, and by inhibition of release of cytokines from 
lymphocytes. 
 
3. Vitamin D and immune function –on exposure to foreign antigens 
vitamin D stimulates an antimicrobial peptide cathellicidin . It regulates 
VDR gene transcription and innate immune response. 
 
4. Vitamin D  in Diabetes mellitus 
 
Vitamin D and Diabetes mellitus: 
 
1, 25dihydroxy cholecalciferol prevents the development of type 2 
Diabetes mellitus by reducing the cytokine production, lymphocytes 
proliferation and destruction of beta cells of pancreas , because of its immune 
modulator activity.(42). 
 
Mechanism of action of Vitamin D in type I diabetes 
 
Autoimmune destruction of cells of pancreatic islet cells result in Type-
1-Diabetes mellitus .Presence of Vitamin D receptors (VDR) on antigen 
presenting cells and activated T-Lymphocytes , down regulates the antigen 
presentation and expression of co-stimulatory molecule by dendritic cells, thus 
inhibiting the production of proinflammatory cytokines .Vitamin D promotes 
the induction of regulatory T-lymphocytes and the production of anti-
inflammatory cytokine- IL- 4 . Vitamin D prevents beta cell damage caused by 
pro-inflammatory cytokines (IL- 1B and IFN γ) by inhibiting the synthesis of 
inflammatory cytokines. 
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RISK FACTORS IN VITAMIN D-DEPENDENT TYPE-2 
DIABETS MELLITUS 
 
 
 
 
 
 
 
 
 
 
Vitamin D in type 2 Diabetes mellitus 
 
 
The pathological mechanism of action of vitamin D on type 2 DM as 
follows, 
 
A.Vitamin D and the beta cell insulin secretion: 
 
 
Vitamin D act directly to induce beta-cell insulin secretion by increasing 
the intracellular calcium concentration via non-selective voltage dependent 
calcium channels. It mediates the activation of beta cell calcium dependent 
endopeptidases to produce the cleavage ,that facilitates the conversion of 
proinsulin to insulin. 
 
B .Vitamin D and Insulin resistance: 
 
 
Vitamin D has an effect on insulin action by stimulating the expression 
of insulin receptors. So the insulin responsiveness for glucose transport is 
enhanced. Vitamin D via its role in regulating extracellular calcium , ensures 
normal calcium influx through cell membranes and maintains adequate 
intracellular cytosolic calcium pool.[(Ca2+)i]. Changes in primary insulin 
target tissues may contribute to peripheral insulin resistance via impaired 
insulin signal transduction leading to decreased GLUT – 4 activity .(43 ,45). 
 
C .Vitamin D and cytokines 
 
 
Type 2 Diabetes mellitus is associated with systemic inflammation . 
Vitamin D improves insulin sensitivity and promotes beta-cell survival by 
modulating the generation and effects of cytokines. 
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MECHANISM OF ACTION OF VITAMIN-D IN DIABETS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vitamin  D  interacts with  Vitamin D response elements in the promoter 
 
region of cytokine genes to interfere with nuclear transcription factors 
implicated in cytokine generation and action .Vitamin D can down regulate the 
activation of NF – Kβ , leading to insulin resistance. Vitamin D interferes with 
cytokine generation by up regulating the expression of calbindin and protects 
the beta cells from cytokine mediated cell death ,thereby preventing type 2 
Diabetes mellitus .(44). 
 
D . The role of vitamin D in glycemic control of type 2 diabetes has a 
seasonal variation which worsens in winter .(43). 
 
Assessment of Vitamin D Status: 
 
25 hydroxycholecalciferol and 1, 25 dihydroxycholecalciferol are the two 
metabolites used to assay vitamin D status. The active from 1, 25 (OH)2 D is 
not measured usually and only 25 hydroxy vitamin D is measured because, it 
is the major circulating , more stable metabolite with longer half -life and it 
reflects the vitamin D status. 
 
According to the Institute of Medicine and Endocrine Society vitamin D 
status is defined as(46), 
 
Vitamin D Sufficiency > 30 ng/ml 
 
Vitamin D insufficiency = 21-29 ng/ml 
 
Vitamin D deficiency <20 ng/ml 
 
Recommended daily intake of Vitamin D: 
 
RDA for infants is 400 IU/day , for children and adolescents - 600 
IU/day. 
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The serum level of Vitamin D increases 0.6 – 1.0 ng/ ml for every 
supplementation of D3 of 100 IU/day. 
 
Glycated Hemoglobin: 
 
 
The non - enzymatic addition of a sugar residue to an amino group of 
protein is known as glycation . The hemoglobin that has been modified by the 
non- enzymatic addition of glucose residue in known as glycated hemoglobin. 
Glycosylated hemoglobin refers to proteins in which carbohydrates have been 
attached enzymatically. 
 
Human adult hemoglobin (Hb) consists   of HbA (97%) , HbA2 
(2.5%) and HbF (0.5%) . HbA has several minor hemoglobins , namely 
HbA1a , HbA1b and HbA1c . HbA1c is formed by the condensation of 
glucose with the N terminal  valine  residue of each beta chain  of HbA to form 
 
an unstable Schiff base . The Schiff base may either dissociate or undergo an 
amadori rearrangement to form a stable ketoamine , HbA1c. HbA1c is the 
major fraction , constituting approximately 80% of HbA1. 
 
The rate of formation of Glycated Hemoglobin is directly proportional to 
the concentration of glucose in the blood over a period of 8-12 weeks 
 
depending on the lifespan of red blood cells .(47). These Glycated - 
Hemoglobin values provide an additional criterion for assessing blood glucose 
control, as they are free of day today glucose fluctuations and its value is not 
affected by food intake or exercise. 
 
Glycated - Hemoglobin is used as an index of long term blood glucose 
concentration and as a measure of the risk for the development of 
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 complications in patient with diabetes. The American Diabetic Association 
recommends the primary treatment goal in adults with Diabetes mellitus should 
be a near normal glycemia -with HbA1c < 7%. 
 
According to the American Diabetic Association recommendation , 
glycated hemoglobin should be monitored routinely at least once in every six 
months in patients meeting treatment goals and in patients with stable glycemic 
control. In patients not meeting the treatment goals and a major change in 
therapy and in gestational diabetes more frequent monitoring is needed. 
 
Lipid Profile 
 
 
he lipid profile includes lipids and lipoproteins like Total cholesterol , 
Triacylglycerol , High-density lipoprotein , Low density lipoprotein and Very 
low-density lipoprotein. 
 
Alternation of lipid profile in Type 2 Diabetes 
 
 
The type 2 Diabetes is associated with 50% to 100% elevation in the 
plasma levels of Total cholesterol and VLDL Triglyceride. 
 
Metabolic alteration in VLDL in type 2 Diabetes mellitus is due to 
insulin resistances which leads to overproduction of VLDL by, 
 
1. Increased free fatty acid and glucose levels , causing increased VLDL 
output from the liver 
 
2. Elevated   triglyceride  levels in the liver  inhibits Apo B degradation 
 and result in increased assembly and  secretion  of  large triglyceride 
 rich VLDL particles. There  is  a defect  in the clearance of triglyceride 
 rich VLDL , that parallels the degree of hyperglycemia. (48). 
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 3. Lipoprotein lipase activity is decreased in individuals with type 2 
diabetes due to both insulin deficiency and insulin resistance. (49) . The 
decreased LPL activity leads to decreased clearance of VLDL 
Triglyceride. 
 
4. Sialation of Apo E is higher is diabetics , which may impair binding and 
uptake by the liver Apo B/E receptor site . Triglyceride elevations in 
type 2 diabetes is also caused by delay in the clearance of postprandial 
state. 
 
Diabetes mellitus patients show increased concentration of plasma LDL 
and Total cholesterol .The Triglycerides from VLDL are exchanged for 
cholesterol ester from LDL particles, and due to increased VLDL levels there is 
an increased generation of triglyceride rich LDL particles in diabetic 
individuals. The LDL particle in diabetes have a decreased ability to bind to 
receptors , which is inversely related to the size and ratio of Triglyceride to 
protein in LDL (50). Small dense LDL do not bind well to the liver Apo B/E 
receptor , catabolized slowly and has an increased oxidative susceptibility , 
which leads to the formation of oxidized LDL particles and playing an 
impartant role in atherosclerosis. Small dense LDLs are more rapidly glycated. 
The extent of glycation of LDL is 2% to 5% in individual with moderate 
hyperglycemia. 
 
The finding of decreased concentration of HDL Cholesterol & changes 
in HDL composition are part of the dyslipidemia in insulin resistance. Changes 
in HDL metabolism include, 
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 1. Impeding the transfer of apo proteins and cholesterol ester from 
triglyceride – rich lipoproteins to the HDL Compartment. 
 
2. Increased activity of hepatic lipase facilitates  HDL clearance . 
 
 
3. Alteration  of  hepatic function  inhibits production of  Apo A1 and 
 
/ or  hepatic secretion of nascent HDL. 
 
 
4. Increased proportion of triglyceride in HDL has been related to the 
activity of adipose tissue LPL. Glycation of HDL interferes with 
HDL receptor binding and lowers the values of HDL in diabetes. 
 
Effect of Vitamin D on lipid Profile: 
 
 
Vitamin D increases the absorption of calcium in the intestine ,thereby 
decreasing the synthesis and secretion of triglycerides and the fatty acid 
absorption due to the formation of insoluble calcium – fatty acid complex .(51) 
 
. Calcium promotes the conversion of cholesterol into bile acids, thereby 
reducing the level of the cholesterol. The serum levels of LDL-C would be 
reduced by the decreased absorption of fat (52) . The higher concentration of 
25 (OH) D suppress serum PTH levels ,which in turn results in lowering of 
triglyceride (53) .The impaired functioning of B cells and insulin resistance 
associated with low levels of vitamin D could affect metabolism of lipoproteins 
there by leading to elevated triglyceride level and reduced HDL-C level. (54). 
In addition, Vitamin D directly affect lipid regulation, as it is related to the 
metabolism of lipids, like synthesis of bile acid in liver. (55) . 
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 III. AIM AND OBJECTIVE OF THE STUDY 
 
 
AIM: 
 
 
To study the prevalence of vitamin D deficiency among type 2 diabetes 
mellitus patients and to find the association of vitamin D level with glycemic 
status and lipid profile in patients attending Diabetic out patient department of 
GOVT.KILPAUK MEDICAL COLLEGE , CHENNAI. 
 
OBJECTIVE: 
 
 
 To estimate the level of 25 hydroxycholecalciferol- vitamin D in 
type 2 Diabetes.


 To estimate HbA1C , fasting , post prandial blood sugar and to 
associate Vitamin D with these parameters in type 2 DM


patients. 
 To associate vitamin D with lipid profile in type 2 DM Patients.
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 IV MATERIALS & METHODS 
 
 
Study Design : Comparative cross sectional study 
 
Place of  study : Department of  Biochemistry and Diabetology, 
 
Govt . Kilpauk Medical College, 
 
Chennai – 10. 
 
Duration of Study: 6 months – November 2017 – April 2017 
 
 
Sample Size: 
 
Prevalence of  vitamin D Deficiency (P) = 30% 
 
Confidence  level is 95% 
 
Power of  the Study is 80% 
 
 
α Value is 0.05 Relative 
precision is 8% Non 
responders is 10% 
Sample Size is 139 
 
Sample Selection 
 
 
Type 2 diabetes mellitus patients aged 30 – 60 years , on oral 
hypoglycemic drug of less than three months duration , attending Diabetology 
OPD of Govt. Kilpauk Medical College Hospital were included in the study, 
after explaining the study to them in their local language and the informed 
written consent was obtained. 
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 After estimating the vitamin D levels the participants were grouped in to 
three groups according to the American Association of Clinical 
Endocrinologist for Vitamin D . 
 
Group – I – Vitamin D sufficient (>30 ng/ml), 
 
Group – II – Insufficient  Vitamin D (20 – 29.9 ng/ml) 
 
Group III – Vitamin  D deficient ( ≤19.9 ng/ml) 
 
Inclusion Criteria: 
 
Recently diagnosed Type 2 Diabetes mellitus patients in the age groups 
of 30 – 60 years of both sexes and on treatment with oral hypoglycemic drugs 
of less than three months. 
 
Exclusion Criteria 
 
1. Type I diabetes mellitus 
 
2. Pregnant women with GDM 
 
 
3. Patients on treatment with statin, insulin ,Vitamin D, OCP’s , 
Steroids . 
 
4. Individuals with history of  alcoholism 
 
5. Known hypo/hyperthyroidism and hypo/ hyperparathyroidism 
 
6. Patients with hepatic and renal impairment 
 
7. Patients with malignancy 
 
8. Patient with hypertension 
 
9. Patients with arthritis,  cardiac disease 
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 DATA Collection 
 
Study was conducted in 139 subjects of either sex. The study was 
approved by the Institutional ethical committee of Government Kilpauk 
Medical College, Chennai. 
 
Sample Collection 
 
Detailed history was taken (Age, sex ,education , H/O of present illness , 
family history, frequency of outdoor activity, duration of sun exposure, 
occupation). 
 
For the study 5ml of fasting venous blood was collected under sterile 
conditions from the anticubital vein. 
 
1. 2 ml of blood was collected in EDTA tube for HbA1C estimation 
 
2. The remaining volume of blood was collected in plain serum tube 
 
.Allowed to clot and serum was separated after centrifugation at 
3000 rpm for 10 minutes and aliquoted and stored at -20C for 
vitamin D estimation. Blood sugar , Serum lipid profile , serum 
urea and creatinine estimation were done immediately. 
 
The following analytes were estimated using  cobas c311autoanalyser. 
 
1. Fasting blood glucose 
 
2. Post prandial blood glucose 
 
3. Glycated Haemoglobin 
 
4. Serum urea &creatinine 
 
5. Lipid profile 
 
6. Vitamin D was estimated using cobas e411 immunoassay analyser. 
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 VITAMIN – D 
 
 
ESTIMATION OF 25-HYDROXYVITAMIN D.(56) 
 
 
Estimation is based on the electrochemiluminescence immunoassay 
principle and done in COBAS e-411 immunoassay analyzer. 
 
REAGENTS 
 
Working solutions 
 
PT1 Pretreatment reagent 1: Dithiothreitol 1 g / L, pH 5.5. 
 
PT2 Pretreatment reagent 2: Sodium hydroxide 55 g / L. 
 
M : Streptavidin-coated microparticles 0.72 mg / mL ; preservative. 
 
 
R1: Ruthenium labeled vitamin D binding protein (150 ug / L); bis-tris 
propane buffer 200 mmol / L; albumin (human) 25 g / L; pH 7.5; 
preservative. 
 
R2: Biotinylated 25-hydroxyvitamin D (14 ug /L); bis-tris propane 
buffer 200 mmol / L; pH 8.6; preservative. 
 
TEST PRINCIPLE 
 
Competition principle: 
 
 
1st incubation: By incubating the sample (15 uL) with pretreatment 
reagent 1 and 2, bound 25-hydroxyvitamin D is released from the Vitamin 
D binding protein. 
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2
nd
 incubation: By incubating the pretreated sample with the ruthenium labeled 
vitamin D binding protein, a complex between the 25-hydroxyvitamin D and 
the ruthenylated vitamin D binding protein is formed. 
 
3
rd
 incubation: After addition of streptavidin - coated microparticles and 
25-hydroxyvitamin D labeled with biotin , the free sites of the ruthenium 
labeled vitamin D binding protein become occupied , complex consisting of the 
ruthenium labeled vitamin D binding protein and the biotinylated 25-
hydroxyvitamin D. The entire complex becomes bound to the solid phase via 
interaction of biotin and streptavidin. 
 
The reaction mixture is aspirated into the measuring cell where the 
microparticles are magnetically captured onto the surface of the electrode. 
Unbound substances are then removed with procell . Application of a voltage 
to the electrode then induces chemiluminescent emission which is measured by 
a photomultiplier. 
 
Results are determined via a calibration curve which is instrument-
specifically generated by 2-point calibration and a master curve provided via 
the reagent barcode. The analyzer automatically calculates the analyte 
concentration of each sample 
 
Normal Value 
 
A more recent consensus of experts to the conclusion that for general 
health a desirable concentration of Vitamin D is > 30.0 ng/mL 
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. (59) 
ESTIMATION OF SERUM GLUCOSE 
(HEXOKINASE METHOD).(58) 
 
Principle 
 
 
Hexokinase catalyzes the phosphorylation of glucose to glucose-6-
phosphate by ATP. Glucose-6-phosphate dehydrogenase oxidizes glucose-6-
phosphate in the presence of NADP to gluconate-6-phosphate. The rate of 
NADPH formation during the reaction is directly proportional to the glucose 
concentration and is measured photometrically. 
 
 
 hexokinase   
Glucose + ATP 
     
– -------- ----- ----- -  
˃ G-6-P + ADP 
     
   Glucose 6 phosphate dehydrogenase  
G-6-P + NADP
+ 
   
>  Gluconate-6-P 
- - - - - - - - - - - - - - - - - - - - - - - - - 
  
 
+NADPH+ H 
 
 
Reagents 
 
R1 
 
 MES buffer: 5.0mmol/L, pH 6;

 Mg2+: 24 mmol/L;

 ATP:> 4.5 mmol/L;

 NADP: > 7.0 mmol/L;

 Preservative
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R2 
 
 HEPES buffer: 200 mmol/L, pH 8.0;

 Mg2+: 4 mmol/L;

 HK (yeast): > 300 ukat/L;

 G-6-PDH (E. coli): >ukat/L;

 Preservative.
 
 
Reagent preparation 
 
Reagent are provided ready to use. 
 
 
Procedure 
 
The assay was carried out using Cobas C311 autoanalyzer 
 
 
Reference range 
 
 
Normal serum level: FBS: 70 – 109 mg/dl and PPBS – 80-139 mg/dl 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
 ESTIMATION OF SERUM UREA (KINETIC TEST 
WITH UREASE AND GLUTAMATE DEHYDROGENASE 
METHOD).(59) 
 
Principle 
 
 
The urea is hydrolysed by urease to produce ammonia and carbonate. In 
the second reaction 2-oxoglutarate reacts with ammonium in the presence of 
glutamate dehydrogenase (GLDH) and the coenzyme NADH to produce L-
glutamate. In this reaction two moles of NADH are oxidized to NAD+ for each 
mole of urea hydrolyzed. 
 
The rate of decrease in the NADH concentration is directly proportional to 
the urea concentration in the specimen and is measured photometrically. 
  urease 
+
 + CO3 2- Urea + 2 H2O -------- -------˃2 NH4 
  Glutamate dehydrogenase 
NH4 
+
 + 2-oxoglutarate + NADH ----------------------------------- ˃  L-glutamate 
 
+ NAD
+
+H2O 
 
Reagent 
 
R1 
 
NaCl 9% 
 
 
R2 
 
 TRIS buffer: 220 mmo/L, pH 8.6;

 2-oxoglutarate: 73 mmol/L;
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  NADH: 2.5 mmol/L;

 ADP: 6.5 mmol/L;

 Urease (jack bean): > 300 ukat/L;

 GLDH (bovine liver): > 80 ukat/L;

 Preservative;

 Nonreactive stabilizers
 
 
Procedure 
 
 
The estimation was carried out by Cobas C 311 autoanalyser. 
 
 
Reference range 
 
Normal serum level: 15 – 40mg/dl. 
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 ESTIMATION OF SERUM CREATININE 
 
(BUFFERED KINETIC JAFFE’S REACTION WITHOUT 
 
DEPROTEINISATION)
.
 (60) 
 
 
Principle 
 
In alkaline solution creatinine reacts with picrate to form a yellow-red 
adduct. The rate of the dye formation (color intensity) is directly proportional 
to the creatinine concentration in the specimen and is measured 
photometrically. 
 
KOH 
 
Creatinine + picric acid---------- --------˃ yellow-red complex. 
 
Reagents 
 
R1 
 
 Potassium hydroxide: 900 mmol/L;

 Phosphate: 135 mmol/L; pH> 13.5;

 Preservative;

 Stabilizer
 
R2/R3 
 
 Picric acid: 38 mmol/L; pH 6.5;

 Non reactive buffer
 
Procedure 
 
The estimation was carried out using Cobas C 311 autoanalyser. 
 
Reference range 
 
Normal serum level: Men: 0.9-1.3mg/dl 
 
Women: 0.6-1.1mg/dl 
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 ESTIMATION OF GLYCATED HEMOGLOBIN. (61) 
 
 
The HbAlc determination is based on the turbidimetric inhibition 
immunoassay (TINIA) for hemolysed whole blood and done in cobas C 311 
analyzer. 
 
Reagents – working solutions 
 
R1 – Antibody reagent 
 
 
MES buffer: 0.025 mol/L; TRIS buffer: 0.015 mol/L, pH 6.2; HbAlc 
antibody (bovine serum) > 0.5 mg/mL; stabilizers; preservatives (liquid) 
 
R2 – Polyhapten reagent 
 
 
MES buffer: 0.025 mol/L; TRIS buffer:L 0.015 mol/L, pH 6.2; HbA1c 
 
polyhapten: > 8 ug/mL; stabilizers; preservatives (liquid) 
 
 
Test principle 
 
 
This method uses Tetradecyltrimethylammonium bromide as the 
detergent in the hemolyzing reagent to eliminate interference from leukocytes. 
 
Hemoglobin A1c: 
 
 
The HbAlc determination is based on the turbidimetric inhibition 
immunoassay (TINIA) for hemolyzed whole blood. 
 
Sample and addition of R1 (Antibody reagent) – Glycohemoglobin 
(HbAlc) in the sample reacts with anti-HbA1c antibody to form soluble 
antigen-antibody complexes. Since the specific HbAlc antibody site is present 
only once on the HbAlc molecule, complex formation does not take place. 
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 Addition of R2 (Polyhapten reagent) and start of reaction – The 
polyphaptens react with excess anti- HbAlc antibodies to form an 
insolubleantiobody-polyhapten complex which can be measured 
turbidimetrically. 
 
Hemoglobin: 
 
 
Liberated hemoglobin in the hemolyzed sample is converted to a 
derivative having a characteristic absorption spectrum which is measured 
bichromatically during the preincubation phase (sample + R1) of the above 
immunological reaction. 
 
Ratio definition 
 
 
The final result is expressed as mmol / molHbAlc or % HbAlc and is 
calculated from the HbAlc / Hb ratio as follows: 
 
Protocol- 1 (% HbAlc according to International Federation of Clinical 
Chemistry and Laboratory Medicine; not recommended for patient result 
reporting): 
 
HbAlc (%) = (HbAlc/Hb) x 100 
 
Protocol- 2 (% HbAlc acc. to DCCT/NGSP): 
 
HbA1C(%) = (HbA1C/Hb) x 91.5 + 2.15 
 
Protocol 3 ( mmol /mol HbAlc  acc. to IFCC): 
 
HbAlc (mmol/mol) = (HbAlc/Hb) x 1000 
 
Reference range: 4.8-5.9 % 
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 ESTIMATION OF SERUM TOTAL CHOLESTEROL 
(ENZYMATIC METHOD-CHOLESTEROL OXIDASE/ 
PEROXIDASE METHOD ) (62) 
 
Principle 
 
 
 
Free and esterified cholesterol in the sample originates by the coupled 
reactions described below, produces a coloured complex , which is measured at 
510nm. The concentration of cholesterol in the sample is directly proportional 
to the intensity of the red complex (red quinine). 
 
 
Cholesterol esterase 
 
Cholesterol esters + H2O ------------------ ˃ cholesterol + RCOOH 
    
  Cholesterol oxidase  
Cholesterol + O2 
    
cholest-4-en-3-one + H2O2 
-----------------------------------  
   
       
   peroxidase    
       
2H2O2+ 4-AAP + phenol ---------------------- ˃ quinine-imine dye + 4 H2O 
AAP –AMINO ANTI PYRINE.    
 
 
Reagents 
 
 PIPES buffer: 225 mmol/L, pH 6.8;

 Mg2+: 10 mmol/L;

 Sodium cholate: 0.6 mmol/L;

 4-aminophenazone: > 0.45 mmol/L;
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  Phenol: > 12.6 mmol/L;

 Fatty alcohol polyglycol ether: 3 %;


 Cholesterol esterase (Pseudomonas spec.): > 25 ukat/L (> 
1.5 U/mL);

 Cholesterol oxidase (E. coli): > 7.5 ukat/L (> 0.45 U/mL);

 Peroxidase (horseradish): > 12.5 ukat/L (> 0.75 U/mL);

 Stabilizers; Preservative
 
 
Reagent reconstitution 
 
Reagents are provided ready to use. 
 
 
Procedure 
 
The assay was carried out using Cobas C311 autoanalyser. 
 
 
Reference range 
 
Desirable  Up to 200mg/dl , 
 
Borderline high 200-239mg/dl 
 
High >240mg/dl 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38 
 ESTIMATION OF SERUM TRIGLYCERIDES 
(ENZYMATIC METHOD-GLYCEROL PHOSPHATE 
/ PEROXIDASE). (63) 
 
Principle 
 
 
Glycerol released from hydrolysis of triglycerides by lipoprotein lipase is 
converted by glycerol kinase into glycerol-3-phosphate, which is oxidized by glycerol 
phosphate oxidase to dihydroxyacetone phosphate and hydrogen peroxide. In the 
presence of peroxidase, hydrogen  peroxide and phenolic chromogen turns to a red 
coloured compound. 
    Lipoprotein lipase    
      
Triglycerides + 3 H2O ---------------˃ Glycerol + 3 RCOOH  
       
   Glycerol Kinase / Mg
2+ 
   
Glycerol + ATP ---------------------------------˃ Glycerol-3-phosphate + ADP 
--- --- --- -- --- -- --- -- --- --- -- --- -- ---    
          
 Glycerol phosphate   
Glycerol-3-phosphate + O2------------------------------------------------------------   
 
 
˃Dihydroxyacetone phosphate + H2O2 
 
  
 
peroxidase  
H2O2 + 4-aminophenazone + 4-chlorophenol --------------------------> 
4-(p benzoquinone-monoimino)-phenazone + 2 H2O + HCl 
 
The intensity of the colour developed for triglycerides in the sample is 
measured at 510nm 
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 Reagents 
 
 PIPES buffer: 50 mmol/L, pH 6.8;

 Mg2+; 40 mmol/L;

 Sodium cholate: 0.20 mmol/L;

 ATP: > 1.4 mmol/L;

 4-aminophenazone: > 0.13 mmol/L;

 4-chlorophenol: 4.7 mmol/L;

 Glycerokinase (Bacillus stearothemophilus): > 3 ukat/L;

 Glycerol phosphate oxidase (E. coli): > 41 ukat/L;

 Peroxidase (horseradish): > 1.6 ukat/L;
 
 
Reagent Preparation 
 
Reagents are provided ready to use 
 
 
Procedure 
 
The assay was carried out using Cobas C 311 autoanalyser. 
 
 
Reference range 
 
Normal 
 
Borderline high 
 
High 
 
 
Up to 150mg/dl 
 
150-199mg/dl 
 
200-499mg/dl 
 
 
 
 
 
40 
 ESTIMATION OF SERUM HIGH DENSITY 
LIPOPROTEIN-CHOLESTEROL (DIRECT 
DETERGENT METHOD) (64 ,65) 
 
Principle 
 
The cholesterol concentration of HDL cholesterol is determined 
enzymatically by cholesterol esterase and cholesterol oxidase coupled with 
Polyethelene glycol (PEG) to the amino acids. Hydrogen peroxide generated in 
the presence of peroxidase reacts with 4 amino antipyrine and HSDA to form a 
purple blue dye, which is read colorimetrically. 
   PEG-cholesterol esesterase-  
     
HDL +cholesterol esters + H2O -------------------------------------------------- ˃HDL- 
cholesterol + RCOOH 
        
 
PEG-cholesterol oxidase 
    
      
HDL –cholesterol + O2  ------------------------------- ˃  Delta 
4
- 
cholestenone + H2O2       
peroxidase 
 
      
2  H2O2+ 4-amino-antipyrine + HSDA* + H
+
+ H2O ------------------------------------------------------˃ 
 
 
purple-blue pigment + 5 H2O 
 
*HSDA = Sodium N-(2-hydroxy-3-sulfopropyl)-3, 5-dimethoxyaniline 
 
   
Reagents 
 
R1 
 
 HEPES buffer: 10.07 mmol/L;

 CHES 96.95 mmol/L, pH 7.4;
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  Dextran sulfate: 1.5 g/L;

 Magnesium nitrate hexahydrate: > 11.7 mmol/L;

 HSDA: 0.96 mmol/L;

 Ascorbate oxidase (Eupenicillium sp., recombinant): > 50 ukat/L;

 Peroxidase (horseradish): > 16.7 ukat/L;

 Preservative
 
R2 
 
 HEPES buffer: 10.07 mmol/L, pH 7.0;

 PEG-cholesterol esterase (pseudomonas spec.): > 3.33 ukat/L;

 PEG-cholesterol oxidase (Streptomyces sp. recombi): > 127 ukat/L;

 Peroxidase (horseradish): > 333 ukat/L;

 4-amino-antipyrine: 2.46 mmol/L;

 Preservative
 
Reagent preparation 
 
Reagents are provided ready to use. 
 
Procedure 
 
The assay was carried out using Cobas C311 autoanalyser. 
 
Reference range 
 
< 40 mg /dl Low (High risk of cardiovascular disease) 
 
> 60 mg/dl High (Low risk of cardiovascular disease) 
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 LDL 
 
 
ESTIMATION OF SERUM LDL 
 
 
From the values of total cholesterol, HDL and triglyceride, the value 
of LDL was determined by using the Friedewald’s formula .( 66). 
 
LDL Cholesterol=Total cholesterol- (HDL-C+TG/5) 
 
TG /5 =VLDL 
 
 
Normal Value: 
 
 
25 – 100 mg / dl-optimal LDL cholesterol 
100-129 mg/dl-near optimal level 
130-159 mg/dl – boderline high level 
 
160 and above- high level of LDL cholesterol 
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 V. RESULTS 
 
 
The present study comprises of 139 known type 2 diabetes mellitus 
patients. According to their vitamin D level they were subgrouped into three 
groups. Group 1 with vitamin D level below 20ng / ml , Group 2 with 20 – 30 
ng / ml and Group 3 comprises of vitamin D level above 30 ng / ml. 
 
Master table shows all the investigations done including vitamin D . 
Master table of the study was prepared by compiling the values obtained in the 
tests performed for each study subject . Statistical analysis was performed 
using SPSS package – version 20.0 . 
 
The results obtained were expressed as mean ± standard deviation. 
Comparison of the parameters among groups were done by analysis of variance 
(ANOVA). Pearson’s correlation was used to correlate between parameters 
done in this study. P value of 0.000 to 0.010 is highly significant , 0.011 to 
0.050 is significant and 0.051 to 1.000 is insignificant. 
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 Number of study subjects including both sexes were presented in 
the Table1 and Figure A 
 
Table - 1 
 
  
Frequency Percent 
Valid Cumulative 
  
Percent Percent     
      
 Male 64 46.0 46.0 46.0 
      
Valid Female 75 54.0 54.0 100.0 
      
 Total 139 100.0 100.0  
      
 
 
 
 
Figure A 
 
 
 
Sex  
 
 
 
 
 
 
 
 
 
Male 
 
 
Female 
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 Percentage  of  subjects  according to their Vitamin D  level  was 
shown in Table 2 & Figure B     
  Table 2    
       
  
Frequency Percent 
Valid Cumulative  
  
Percent Percent 
 
     
       
 Below 20 52 37.4 37.4 37.4  
       
 20-30 33 23.7 23.7 61.2  
Valid       
Above 30 54 38.8 38.8 100.0 
 
  
       
 Total 139 100.0 100.0   
       
 
 
 
 
Figure B 
 
 
Vitamin D 
 
 
 
Above 30  
 
 
 
Below  20 
 
 
 
 
 
 
 
 
 
20-30 
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Table 3 shows the mean and standard deviation of all the analytes. 
 
TABLE 3 
 
 
N Minimum Maximum Mean 
Std. 
 
Deviation      
      
Fasting Sugar 139 115 249 142.36 28.195 
      
P.P Sugar 139 164 515 226.65 60.650 
      
Urea 139 17 53 23.83 6.121 
      
Creatinine 139 .6 1.9 .829 .2158 
      
Total cholesterol 139 153 453 196.44 26.469 
      
TGL 139 68 687 187.74 74.612 
      
HDL 139 14 136 31.82 10.926 
      
LDL 139 76 180 127.73 17.745 
      
HBA1C 139 5.5 10.5 6.509 1.0538 
      
Vitamin D 139 6.83 53.13 24.9201 13.35600 
      
Valid N 
139 
    
(list wise) 
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 Table 4 - shows Vitamin D level according to Age group among the 
study population. 
 
TABLE 4 
 
   Age Group in years  
       
     Above  
   35-45 46-55 55 Total 
       
Vitamin Below Count 12 31 9 52 
D 20 
     
% within 
23.1% 59.6% 17.3% 100.0%   
Vitamin D       
       
  % within Age 
48.0% 37.8% 28.1% 37.4%   Group in years       
       
 20-30 Count 6 21 6 33 
       
  % within 
18.2% 63.6% 18.2% 100.0%   Vitamin D       
       
  % within Age 
24.0% 25.6% 18.8% 23.7%   
Group in years       
       
 Above Count 7 30 17 54 
 
30 
     
 % within 
13.0% 55.6% 31.5% 100.0%     
Vitamin D       
       
  % within Age 
28.0% 36.6% 53.1% 38.8%   Group in years       
       
Total  Count 25 82 32 139 
       
  % within 
18.0% 59.0% 23.0% 100.0%   Vitamin D       
       
  % within Age 
100.0% 100.0% 100.0% 100.0%   Group in years       
       
 
 
Figure 4 a- Shows chi square test for age distribution. 
 
 Value Df Asymp. Sig. (2-sided) 
    
Pearson Chi-Square 4.492(a) 4 .344 
    
Likelihood Ratio 4.433 4 .351 
    
Linear-by-Linear 
3.825 1 0.050 
Association    
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Figure c : Shows vitamin D distribution according to age 
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 Table 5 - Shows gender distribution among the study groups. 
 
TABLE 5 
 
   Sex  
      
   Male Female Total 
      
Vitamin D Below 20 Count 22 30 52 
      
  % within Vitamin D 42.3% 57.7% 100.0% 
      
  % within Sex 34.4% 40.0% 37.4% 
      
 20-30 Count 16 17 33 
      
  % within Vitamin D 48.5% 51.5% 100.0% 
      
  % within Sex 25.0% 22.7% 23.7% 
      
 Above 30 Count 26 28 54 
      
  % within Vitamin D 48.1% 51.9% 100.0% 
      
  % within Sex 40.6% 37.3% 38.8% 
      
Total Count 64 75 139 
      
  % within Vitamin D 46.0% 54.0% 100.0% 
      
  % within Sex 100.0% 100.0% 100.0% 
      
 
 
 
Diabetes with Vitamin D level below 20 ng/ml–(group 1) consists of 52 
subjects with 22 males (34.4%) and 30 females (40.0%) & the group 2 with 20-
30ng/ml Vitamin D level consists of 33 subjects with 16 males (25.0%) and 17 
females (22.7%) & the group 3 -above 30 ng/ml of Vitamin D consists of 54 
subjects with 26 males (40.6%) and 28 females (37.3%). 
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Figure D shows the vitamin D distribution among sex. 
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 Table 6: Shows fasting sugar among the study group. 
 
TABLE 6 
 
   Fasting Sugar  
      
   100-125 > 125 Total 
      
Vitamin D Below 20 Count 1 51 52 
     
  % within 
1.9% 98.1% 100.0%   
Vitamin D      
      
  % within 
3.1% 47.7% 37.4%   
Fasting Sugar      
      
 20-30 Count 5 28 33 
      
  % within 
15.2% 84.8% 100.0%   Vitamin D      
      
  % within 
15.6% 26.2% 23.7%   
Fasting Sugar      
      
 Above 30 Count 26 28 54 
      
  % within 
48.1% 51.9% 100.0%   
Vitamin D      
      
  % within 
81.3% 26.2% 38.8%   Fasting Sugar      
      
Total  Count 32 107 139 
      
  % within 
23.0% 77.0% 100.0%   Vitamin D      
      
  % within 
100.0% 100.0% 100.0%   Fasting Sugar      
      
 
In study group-1 one subject had fasting blood sugar between 100-125 
mg /dl and 51 subjects had blood sugar above 125 mg /dl and in study group - 
2 , 5 subjects had the fasting sugar between 100-125 mg/dl and 28 subjects had 
more than 125 mg/dl and in group- 3 , 126 study subjects with fasting sugar 
between 100-125 mg /dl and 28 subjects had fasting sugar above 125 mg/dl . 
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 Table- 6a: Shows Chi square of fasting blood sugar . 
 
 
Value df 
Asymp. Sig. 
 
(2-sided)    
    
Pearson Chi-Square 33.453(a) 2 .000 
    
Likelihood Ratio 37.251 2 .000 
    
Linear-by-Linear 
31.835 1 .000 
Association    
    
N of Valid Cases 139   
    
 
 
Figure E: Shows the distribution of fasting blood sugar among the 
study groups. 
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 Table 7 : Shows the Total cholesterol among study group. 
 
TABLE 7 
 
      Total Cholesterol  
Total                 
< 200 
 
> 200 
 
          
            
 Vitamin D Below 20 Count 13 39 52 
            
   % within Vitamin D 25.0% 75.0% 100.0% 
            
   % within Total 
14.9% 
 
75.0% 
 
37.4%    
Cholesterol 
  
         
            
  20-30 Count 25 8 33 
            
   % within Vitamin D 75.8% 24.2% 100.0% 
            
   % within Total 
28.7% 
 
15.4% 
 
23.7%    
Cholesterol 
  
         
            
  Above 30 Count 49 5 54 
            
   % within Vitamin D 90.7% 9.3% 100.0% 
            
   % within Total 
56.3% 
 
9.6% 
 
38.8%    
Cholesterol 
  
         
            
 Total Count 87 52 139 
            
   % within Vitamin D 62.6% 37.4% 100.0% 
            
   % within Total 
100.0% 
 
100.0% 
 
100.0%    Cholesterol            
            
 Table 7a : Shows the chi –square  test of  total cholesterol.   
    TABLE 7A       
          
    
Value 
 
Df 
 Asymp. Sig.  
      (2-sided)           
          
 Pearson Chi-Square  52.100(a)  2  .000   
          
 Likelihood Ratio  55.431  2  .000   
           
 Linear-by-Linear  
48.311 
 
1 
 
.000 
  
 Association                
           
 N of Valid Cases  139        
            
   54        
  Table 7 & Table 7a : Shows  Group 1  consist of  52 subjects  , out of 
which 13(14.9%) subjects had total cholesterol level below  200mg/dl   and 
above 200mg/dl  of  total cholesterol  was  present  in 39  (75.0%)  subjects. 
Group 2 with 33 subjects , 25 (28.7%)  subjects  had total cholesterol below 
 
200 mg/dl & 8 subjects (15.4%) had above 200 mg/dl of cholesterol. Group 3 
with 54 participants , 49 (56.3%) subjects had less than 200 mg/dl of 
cholesterol and 5 (9.6%) subjects had cholesterol level above 200 mg/dl. 
 
Figure F : Shows the distribution of total cholesterol among the groups. 
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 Table 8: Shows the TRIGLYCERIDE among the study group. 
 
TABLE 8 
 
   TGL   
      
Total    
< 150 
 
> 150      
       
Vitamin D Below 20 Count 7 45 52 
       
  % within Vitamin D 13.5% 86.5% 100.0% 
       
  % within TGL 17.9% 45.0% 37.4% 
       
 20-30 Count 9 24 33 
       
  % within Vitamin D 27.3% 72.7% 100.0% 
       
  % within TGL 23.1% 24.0% 23.7% 
       
 Above 30 Count 23 31 54 
       
  % within Vitamin D 42.6% 57.4% 100.0% 
       
  % within TGL 59.0% 31.0% 38.8% 
       
Total Count 39 100 139 
       
  % within Vitamin D 28.1% 71.9% 100.0% 
       
  % within TGL 100.0% 100.0% 100.0% 
       
 
 
Out of 52 patients in Group 1 , 7 (17.9%) subjects had TGL less than 
150 mg /dl & 45 (45.0%) subjects had TGL more than 150mg /dl. In Group- 2 , 
9 (23.1%) subjects had TGL less than 150mg /dl & 24 (24.0%) subjects had 
TGL more than 150mg/dl and in Group- 3 , 23 subjects had TGL less than 150 
mg/dl & 31 (31%) subjects had TGL more than 150 mg/dl. 
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 Table 8a: Shows the chi square test for TGL with P value of .004. 
 
TABLE 8A 
 
   Asymp. Sig. 
 Value Df (2-sided) 
    
Pearson Chi- 
11.150(a) 2 .004 
Square    
    
Likelihood Ratio 11.562 2 .003 
    
Linear-by-Linear 
11.063 1 .001 
Association    
    
N of Valid Cases 139   
    
 
Figure G : Shows the distribution of TGL among the study group 
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 Table 9 : Shows High density lipoprotein among the study group. 
 
TABLE 9 
 
   HDL  
      
   < 40 > 40 Total 
      
Vitamin D Below 20 Count 51 1 52 
      
  % within Vitamin D 98.1% 1.9% 100.0% 
      
  % within HDL 39.5% 10.0% 37.4% 
      
 20-30 Count 29 4 33 
      
  % within Vitamin D 87.9% 12.1% 100.0% 
      
  % within HDL 22.5% 40.0% 23.7% 
      
 Above 30 Count 49 5 54 
      
  % within Vitamin D 90.7% 9.3% 100.0% 
      
  % within HDL 38.0% 50.0% 38.8% 
      
Total Count 129 10 139 
      
  % within Vitamin D 92.8% 7.2% 100.0% 
      
  % within HDL 100.0% 100.0% 100.0% 
       
 
 
 
Out of 52 subjects in group I , 51 subject had HDL level less than 40 
mgs/dl and one subject had HDL above 40 mgs%. In group II 29 subjects had 
HDL less than 40 % and 4 subjects had above 40 mgs/dl. In group III with 54 
subjects 49 had vitamin D level below 40 mgs/dl and 5 subjects had more than 
40 mgs/dl. 
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Figure H : Shows the distribution of HDL among groups. 
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 Table 10 - shows the LDL distribution among study group. 
 
TABLE - 10 
 
   LDL Total 
      
   < 130 > 130  
      
Vitamin Below 20 Count 15 37 52 
D 
     
 
% within Vitamin D 28.8% 71.2% 100.0%   
      
  % within LDL 18.8% 62.7% 37.4% 
      
 20-30 Count 23 10 33 
      
  % within Vitamin D 69.7% 30.3% 100.0% 
      
  % within LDL 28.8% 16.9% 23.7% 
      
 Above 30 Count 42 12 54 
      
  % within Vitamin D 77.8% 22.2% 100.0% 
      
  % within LDL 52.5% 20.3% 38.8% 
      
Total Count 80 59 139 
      
  % within Vitamin D 57.6% 42.4% 100.0% 
      
  % within LDL 100.0% 100.0% 100.0% 
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Figure-I : Shows the distribution LDL among study group. 
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 Table 11 : Shows the age distribution between study groups 
 
TABLE 11 
 
Age in years 
 
   Std. 
 N Mean Deviation 
    
Below 20 52 49.23 5.253 
    
20-30 33 50.18 5.241 
    
Above 30 54 52.28 5.137 
    
Total 139 50.64 5.343 
    
 
The mean age is 50.64 ± 5.343 among the study population . 
 
TABLE 11 A - ANOVA for AGE distribution.  
       
 Sum of   Mean   
 Squares df  Square F Sig. 
       
Between Groups 255.041 2  127.521 4.706 .011 
       
Within Groups 3684.973 136  27.095   
       
Total 3940.014 138     
       
 
 
This table shows the statistically significant p value of 0.011. 
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 Table 12: Shows the Comparison of fasting blood 
 
sugar between study groups. 
 
TABLE 12 - Fasting Sugar 
 
 
N Mean 
Std. 
 
Deviation    
    
Below 20 52 168.13 31.755 
    
20-30 33 129.61 6.324 
    
Above 30 54 125.33 5.191 
    
Total 139 142.36 28.195 
    
 
 
 
TABLE 12 A Anova for Fasting Sugar Among Study GROUPS. 
 
TABLE 12 A - Fasting Sugar 
 
 Sum of 
df 
Mean 
F Sig  
Squares Square     
      
Between Groups 55568.078 2 27784.039 69.801  
      
Within Groups 54133.936 136 398.044  .000 
      
Total 109702.014 138    
      
 
 
The mean fasting sugar values among the three groups were 168.13, 
129.61, 125.33 respectively and the p. value is 0.000 which is statistically 
significant.. 
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 Table 12b : Represent the mean difference of fasting sugar by 
Tukey HSD Post Hoc tests. 
 
Table - 12b 
 
Dependent Variable: Fasting Sugar Tukey HSD 
 
     95% Confidence 
(I) (J) Mean 
Std. 
 Interval 
Vitamin Vitamin Differen Sig. 
  
Error 
  
D D ce (I-J) 
 
Lower Upper   
     Bound Bound 
       
Below 20 20-30 38.53(*) 4.440 .000 28.01 49.05 
       
 Above 30 42.80(*) 3.876 .000 33.62 51.99 
       
20-30 Below 20 -38.53(*) 4.440 .000 -49.05 -28.01 
       
 Above 30 4.27 4.408 .598 -6.17 14.72 
       
Above 30 Below 20 -42.80(*) 3.876 .000 -51.99 -33.62 
       
 20-30 -4.27 4.408 .598 -14.72 6.17 
       
 
 
 
 
By Tukey HSD Post Hoc tests for multiple comparison of fasting blood 
sugar between Group 1 and 2 was significant (P <.000) and difference between 
group 1 and 3 was significant (P <.000). 
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 TABLE 13 : Represents mean and standard deviation of post 
 
prandial blood sugar. 
 
      Table 13     
              
          Std. Std.  
   N  Mean    Deviation Error  
              
 Below 20 52  269.44    69.762  9.674  
              
 20-30  33  212.45    38.854  6.764  
              
 Above 30 54  194.11    31.341  4.265  
              
 Total 139  226.65    60.650  5.144  
           
 Table 13a : Represents ANOVA for the post prandial sugar 
   among study groups   
      Table 13 a     
             
   Sum of      Mean    
   Squares  df  Square  F Sig. 
             
Between  
159045.385 
 
2 
 
79522.692 
 
31.027 .000 
Groups 
    
            
             
Within  
348570.342 
 
136 
 
2563.017 
   
Groups 
      
            
          
Total  507615.727 138      
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 Table 13 b : Represents the mean difference by tukey HSD Post HOC test 
for Multiple comparison of Post Prandial blood Sugar. 
 
Comparison of mean difference between Group 1 & Group 2 was (59.99 
±11.26), and between group 1 & group 3 was (75 ± 9.8) with significant P 
value of <.000. 
 
 Table 13b   
     
(I) Vitamin D (J) Vitamin D 
Mean Std. 
Sig. 
Difference (I-J) Error    
     
Below 20 20-30 56.99(*) 11.267 .000 
     
 Above 30 75.33(*) 9.836 .000 
     
20-30 Below 20 -56.99(*) 11.267 .000 
     
 Above 30 18.34 11.186 .233 
     
Above 30 Below 20 -75.33(*) 9.836 .000 
     
 20-30 -18.34 11.186 .233 
      
 
Table -14: Shows distribution of mean HbA1c among GROUPS Table 14 
 
   Std. Std. 
 N Mean Deviation Error 
     
Below 20 52 7.481 1.1633 .1613 
     
20-30 33 6.027 .3145 .0548 
     
Above 30 54 5.867 .1962 .0267 
     
Total 139 6.509 1.0538 .0894 
     
 
The mean HbA1C among the three groups were 7.481 ± 1.16 , 6.027 ± 
0.31 and 5.86 ± 0.19 respectively. 
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 Table -14a: Shows ANOVA for HbA1C 
 
Table 14 a 
 
  Sum of 
Df 
Mean 
F Sig.   
Squares Square      
       
 Between 
79.024 2 39.512 72.394 .000  
Groups       
       
 Within 
74.228 136 .546 
  
 
Groups 
  
      
       
 Total 153.252 138    
       
 
The p value is 0.000  which is statistically significant. 
 
 
Table 14 b shows Post Hoc Tests for HbA1C 
 
Table 14 b 
 
(I) Vitamin (J) Mean Difference Std. 
Sig. 
D Vitamin D (I-J) Error  
     
Below 20 20-30 1.453(*) .1644 .000 
     
 Above 30 1.614(*) .1435 .000 
     
20-30 Below 20 -1.453(*) .1644 .000 
     
Above 30 .161 .1632 .588 -.226 
     
Above 30 Below 20 -1.614(*) .1435 .000 
     
20-30 -.161 .1632 .588 -.547 
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 Table – 15 : Shows the Total Cholesterol among study groups 
 
Table 15 
 
    Std. 
 N Mean Std. Deviation Error 
     
Below 20 52 209.27 36.200 5.020 
     
20-30 33 193.91 14.103 2.455 
     
Above 30 54 185.63 12.596 1.714 
     
Total 139 196.44 26.469 2.245 
     
 
 
The mean Total Cholesterol among the three study group were 209 ± 
36.200 , 193.91 ± 14.103 and 185.63±26.469. 
 
Table 15a: Shows ANOVA for total cholesterol 
 
Table 15a 
 
 Sum of  Mean   
 Squares df Square F Sig. 
      
Between Groups 
15080.680 2 7540.340 12.566 .000  
      
Within Groups 
81605.551 136 600.041      
      
Total 
96686.230 138        
      
 
 
P VALUE  is 0.000 ,Which is statistically significant. 
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 TABLE 15 b SHOWS THE RESULT OF POST HOC TEST FOR 
TOTAL CHOLESTEROL. 
 
Table 15b 
 
(I) Vitamin (J) Vitamin 
Mean 
Std. 
 
Difference Sig. 
D D Error 
(I-J) 
 
    
     
Below 20 20-30 
15.36(*) 5.452 .015   
     
 Above 30 23.64(*) 4.759 .000 
     
20-30 Below 20 -15.36(*) 5.452 .015 
     
 Above 30 8.28 5.412 .280 
     
Above 30 Below 20 
-23.64(*) 4.759 .000   
     
 20-30 -8.28 5.412 .280 
      
 
Table – 16– shows Triglyceride among study groups 
 
Table 16 
 
 
   Std.  
 N Mean Deviation Std. Error 
     
Below 20 52 197.85 81.555 11.310 
     
20-30 33 186.48 64.626 11.250 
     
Above 30 54 178.78 73.419 9.991 
     
Total 139 187.74 74.612 6.329 
     
 
 
Mean triglyceride among the three groups were 197.85 ±81.555, 
186.48±64.62 and 178 .78±73.41 respectively. 
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 Table -17 : Shows HDL among the study groups 
 
Table 17 
 
   Std. Std. 
 N Mean Deviation Error 
     
Below 20 52 32.23 15.429 2.140 
     
20-30 33 32.24 7.599 1.323 
     
Above 30 54 31.17 6.796 .925 
     
Total 139 31.82 10.926 .927 
     
 
Mean HDL among the three groups were 32.23±15.42 ,32±7.5 and 
31.17± 6.79. 
 
Table – 18: shows LDL among study groups 
 
Table 18 
 
 N Mean Std. Deviation Std. Error 
     
Below 20 52 138.58 14.767 2.048 
     
20-30 33 124.70 13.848 2.411 
     
Above 30 54 119.15 17.265 2.350 
     
Total 139 127.73 17.745 1.505 
     
 
The mean LDL level among the three study groups were 138± 14.76 , 
124.70 ± 13.848 and 119.15 ± 17.26. 
 
Table- 18a shows ANOVA FOR LDL among Groups. 
 
Table 18a 
 
 Sum of 
df 
Mean 
F Sig.  
Squares Square     
      
Between Groups 10398.674 2 5199.337 21.391 .000 
      
Within Groups 33056.477 136 243.062  
      
Total 43455.151 138   
      
 
P VALUE is 0.000 ,Which is statistically 
significant 70 
 Table – 19 – shows the Correlation of vitamin D with all the analytes 
 
Table 19 
 
  Vitamin D 
   
Age in years Pearson Correlation .254(**) 
   
 Sig. (2-tailed) .003 
   
 N 139 
   
Fasting Sugar Pearson Correlation -.684(**) 
   
 Sig. (2-tailed) .000 
   
 N 139 
   
P.P Sugar Pearson Correlation -.547(**) 
   
 Sig. (2-tailed) .000 
   
 N 139 
   
Urea Pearson Correlation -.087 
   
 Sig. (2-tailed) .309 
   
 N 139 
   
Creatinine Pearson Correlation .062 
   
 Sig. (2-tailed) .466 
   
Total Pearson Correlation -.385(**) 
Cholesterol 
  
Sig. (2-tailed) .000  
   
 N 139 
   
 Pearson Correlation -.324(**) 
TGL 
  
Sig. (2-tailed) .000  
   
 N 139 
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 HDL Pearson Correlation .330(*) 
   
 Sig. (2-tailed) .036 
   
 N 139 
   
LDL Pearson Correlation -.477(**) 
   
 Sig. (2-tailed) .000 
   
 N 139 
   
HBA1C Pearson Correlation -.693(**) 
   
 Sig. (2-tailed) .000 
   
 N 139 
   
 
 
TABLE 19 Shows highly significant correlation of vitamin D with age 
at the level of 0.003, Fasting , postprandial blood sugar and HbA1c with the 
correlation at 0.000 and Among THE LIPID PROFILE - Total cholesterol , 
triglyceride and LDL have statistically significant correlation with vitamin D at 
the level of 0.000. HDL was significantly correlated with vitamin D at the 
level of 0.330 . 
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 VI. DISCUSSION 
 
 
In this study, we attempted to explore the effect of Vitamin D in type 2 
Diabetes mellitus. 139 Diabetic subjects were selected and grouped into three 
according to their vitamin D level and the biochemical parameters were 
assessed for all the three groups. Among the parameters Fasting blood sugar, 
PPBS, HbA1c, Total Cholesterol, TGL, LDL were statistically highly 
significant between the groups, HDL was statistically significant. 
 
According to Table no 2 in our study the prevalence of vitamin D 
deficiency in recent onset diabetic patients attending Diabetic OPD of GOVT 
KMCH was 61% . Only 39% diabetics had sufficient vitamin D level. 
 
Lack of exposure to the sun is the leading cause of vitamin D deficiency 
as it is a sunshine vitamin. With modernization, the number of hours spent 
outdoor have decreased thereby it leads to an inadequate sun exposure. Other 
reasons are dark skin complexion and sunscreen use. 
 
A cross sectional survey was carried out in New Zealand with 5677 
subjects aged between 40-64 years of newly diagnosed diabetes mellitus to 
determine their vitamin D level. Serum Vitamin D concentration was 
significantly lower in the newly detected cases with Diabetes. They concluded 
that the increased prevalence of diabetes was due to the low serum Vitamin D 
concentration.(68) 
 
A cross sectional study(69) by Brock KE et al, was conducted in 2011 
with 2465 subjects revealed that the level of 25(OH)D and 1,25(OH)2D levels 
were lower in diabetes, after adjustment for confounding factors like sex, 
 
geographical location, physical activity, BMI, Vitamin D and Calcium 
intake. 73 
 An Italian study by YU Jr et al ,(70) with 799 Diabetic patients showed 
that 25 (OH)D levels were significantly lower in diabetic patients than in 
control subjects (11± 9.8 vs 9 ± 11.3 ng/ml, P = 0.008) , and the prevalence of 
25 (OH) D deficiency was significantly higher in diabetic patients than in the 
control subjects (39 vs 25%). 
 
In 2000, Aksoy H et al ,compared the concentration of Vitamin D in 
diabetic patients with nondiabetic patients. Compared with the control group, 
vitamin D concentration were found to be decreased in diabetic patients 
(P<0.001). (71). 
 
In a study done by Athanassiou et al, published in 2013 showed that the 
vitamin D deficiency in study group was 98.5% .( 72). 
 
In 2013 an Indian study was done by Daga Ra et al , for comparison of 
concentration of 25 (OH)D in newly detected youth onset diabetic subjects 
with non diabetic healthy subjects . Mean ± SD 25(OH)D was significantly 
low, 7.88 ± 1.20 ng/ml in subjects with diabetes against 16.64 ± 7.83 ng/ml in 
controls.(73) 
 
In Pittas. et al , observational study a relatively consistent association 
between low vitamin D status and prevalence of type 2 Diabetes was 
present.(74) 
 
According to Table no 1 & 4 of our study the Vitamin D deficiency in 
males was 46% & Females was 54%.Vitamin D level was high in the age 
group of 46 to 55 years , compared to the age group of 35-45 years and above 
55 years. 
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 AL-Zaharani M et al , in his study found that the Vitamin D deficiency 
in female Diabetics was 73.65% and 46.9% in male diabetics.(75) 
 
Scragg et al , in his study with 6288 people found that the mean vitamin 
D level in males were more than the females. (76) 
 
Previous cross sectional and case control studies proved an inverse 
association between Vitamin D and type 2 diabetes as well as the markers of 
adverse glucose homeostasis. 
 
According to the Table no 12 and 12 a - the observation of the study 
was when the fasting blood sugar was more than the controlled fasting sugar , 
the prevalence of vitamin D deficiency was more. 
 
Group 1 of our study consisted of 52 patients with vitamin D below 
20ng /ml, the mean fasting blood sugar was 168.13 ±31.755.In Group 2 with 33 
patients vitamin D level between 20-30 ng / ml had the mean fasting blood 
sugar of 129±6.32.Group 3 with 54 patients had vitamin D above 30 mg /dl 
with the fasting blood sugar of 125±5.191. The P value is 0.000.which is highly 
significant. 
 
According to Table no 13 and 13 a another observation of the study 
was when the mean post - prandial blood sugar was high ,the vitamin D level 
was low. 
 
Group 1 of our study with vitamin D level below 20 ng /ml had mean 
post prandial blood sugar was 269.44 ± 69.72 and Group 2 with Vitamin D 
Level between 20-30 ng /dl had post prandial blood sugar of about 212.45± 
38.85 , and Group 3 with vitamin D level more than 30 ng /dl had post prandial 
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 blood sugar of about 194.11±31.34. p value is 0.000, which is highly . From 
these table no 12 and 13 the observation of our study was vitamin D was 
inversely associated with both fasting and postprandial blood sugar. 
 
Based on the available clinical and epidemiological data, when the 
fasting blood sugar was more than 125 mg /dl the positive effects of vitamin D 
is primarily related to its action on insulin secretion , action or both and 
secondarily due to a role on inflammation. 
 
The mechanisms of the effect of vitamin D in type 2 Diabetes mellitus 
include, (i) improved beta cell function via direct effect of vitamin D on 
vitamin D receptors on pancreatic beta cells and activating 1 alpha hydroxylase 
of pancreatic beta cells or by increase in the intracellular ionized calcium , 
which results in enhanced insulin release. (ii) increased insulin sensitivity 
related to expression of insulin receptor or via calcium dependent pathways in 
target cells leading to increase in the glucose utilization (iii) inhibition of beta 
cell apoptosis is due to VDR transcription factor mediated inhibition of 
cytotoxic cytogene expression. (iv) several genetic polymorphism in genes 
related to vitamin D metabolism such as DBP and VDR may predispose the 
subjects to type 2 Diabetes. (v) The non skeletal effect of vitamin D which 
appears in high vitamin D concentration and in low vitamin D concentration it 
is limited to bone and muscle. The significant concentration is 40-60 ng/ml . 
(V1) 1,25(OH)D increases transcription of insulin receptor gene and also 
suppresses the renin gene. (V11) regulation of peroxisome proliferative 
activated receptor by vitamin D has a role in insulin sensitivity . (77,78,79). 
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 In a cross sectional study by Hurskainen et al, .in 2012 at Finland 
showed an inverse association of vitamin D with fasting and post prandial 
glucose level, implies that vitamin D is associated with impaired glucose 
metabolism.(80) 
 
Kayaniyil et al, longitudinal study in 2013 showed a significant inverse 
association of vitamin D with fasting sugar.(81). 
 
Baynes et al , assessed vitamin D status in 142 elderly type 2 diabetics 
in 1990 and found that 1 hour glucose and area under glucose curve during 
OGTT were inversely associated with vitamin D.(82). 
 
In 2004 , Chi et al, with 126 subjects found an independent negative 
association between vitamin D and plasma glucose concentration at fasting , 60 
min , 90 min and 120 min during OGTT.(83). 
 
According to Table no 14 and 14a - in our study there was a statistically 
significant inverse correlation between serum vitamin D and HbA1c . In Group 
1 of our study with vitamin D level below 20 ng / dl had mean HbA1C of 7.48± 
1.16 and Group 2 with vitamin D level between 20-30 ng/ dl had HbA1C of 
about 6.02± 0.31 and Group 3 with vitamin D level above 30 ng /dl had 
HbA1C of about 5.86±0.196. p value is 0.000., which is highly significant. 
This may be due to the fact that vitamin D is a factor for the insulin secretion 
and sensitivity as discussed earlier. 
 
Hypponen et al , study in 2006 and 2008 showed nonlinear inverse 
association between vitamin D and HbA10C.and also the mean vitamin D level 
in male was more than the females.(84). 
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 Jatupal k et al, study published in 2010 with 9773 subjects showed an 
inverse association of vitamin D with HbA1C.(85) . 
 
Scragg R et al ,study in 2000 relating vitamin D status in Diabetics proved the 
inverse association of vitamin D with HbA1C of Diabetics.(86).These finding 
suggest the need of screening of vitamin D deficiency in elevated HbA1C level 
and vice versa. 
 
Diabetics have hypercholesterolemia , hypertriglyceridemia, and 
decreased HDL cholesterol levels. The most common alteration is 
hypertriglyceridemia. 
 
According to Table no 15, 16,17 and 18 in our study, there is an increase 
in serum triglyceride, and cholesterol level and LDL cholesterol level with 
decreased HDL cholesterol level when vitamin D level is decreased. Group 1 
with vitamin D Level below 20 ng /dl had mean total cholesterol of 209±36.00 
and group 2 with vitamin D level between 20-30 ng /dl had total cholesterol of 
193±14.10 and group 3 with vitamin D level above 30 ng /dl had total 
cholesterol of 185±12.59. the p value is 0.000 which is highly significant, 
Which is due to the effect of vitamin D on calcium metabolism. 
 
Vitamin D increases intestinal absorption of calcium which could 
decrease the synthesis and secretion of hepatic triglyceride by forming a 
complex with cholesterol . Increased intestinal calcium could reduce the 
intestinal fatty acid absorption due to insoluble calcium fatty acid complexes. 
Serum LDL-C would be reduced by decreased absorption of fat particularly 
saturated fatty acids . In addition calcium promotes the conversion of 
cholesterol into bile acids , there by reduces the level of cholesterol and also 
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 high concentration of vitamin D suppresses the PTH , which decreases the 
triglyceride by increased peripheral removal. vitamin D level decreases the beta 
cell function and insulin resistance. This alters lipoprotein metabolism leading 
to an increase in triglyceride and decrease in HDL level. The 
 
expression of VLDL cholesterol receptors in some type of cells by vitamin D 
regulates TGL metabolism . Increased insulin resistance due to vitamin D 
 
deficiency is associated with an elevation of levels of VLDL cholesterol and 
TGL.(87) 
 
Similar effects was observed in following studies. Shamsian AA et al, 
study in Mashhad  in 2015 – showed increased total cholesterol , triglyceride 
and LDL with  decreased HDL .(88)      
Jafari et al ,  study  showed reduced reduced vitamin D  lead to reduced 
Serum Total cholesterol , no reduction in triglyceride, decreased LDL and 
negligible effect on HDL.(89)      
Sadisomeolia A et al, study on type 2 Diabetes mellitus in Iran showed 
reduced vitamin  D  level  is  associated   with decreased Triglyceride 
level.(90).      
Jaishidahdal k et al , study in 2017 in India showed reduced vitamin D 
level is associated with altered lipid profile.    
The low level of vitamin D in diabetic patients and inverse relationship 
between vitamin  D level and  HbAlc supports an active effect of vitamin D 
in pathogenesis of type 2 Dm . The prevalence of 61% implies the  necessity 
 
for more research and implementation of preventive measure related to Vitamin D 
deficiency. Vitamin D screening and enrichment plan has to be implemented. 
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 VII. SUMMARY 
 
 
This is a cross sectional study which was conducted to find the role of 
serum1, 25 dihydroxy cholecalciferol on glycemic status and lipid profile in 
type 2 Diabetes mellitus. In the present study 139 diabetic patients in the age 
group of 30 to 60 years of recent onset diabetes were recruited . 5ml of fasting 
blood sample were drawn from all the patients. The level of fasting blood 
glucose, urea , Creatinine , HbAlc , LDL, HDL, VLDL, TGL, Cholesterol and 
vitamin D were estimated. 
 
According to their vitamin D level they were grouped in to 3 groups. 
The vitamin D level was correlated with HbAlc, blood sugar & lipid profile. 
This shows Vitamin D as a risk factor in type 2 diabetes mellitus and its effect 
on glycemic control and lipid profile in type 2 Diabetes mellitus . 
Hypovitaminosis D is prevalent in type 2 diabetes mellitus and along with 
other risk factors it may be a major independent predictor of complication of 
diabetes mellitus. 
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 VII A-CONCLUSION 
 
 
Vitamin D is a regulator of cell proliferation & differentiation involved 
in type 2 diabetes mellitus. The present study demonstrates low vitamin D level 
in high glycemic index patients. This might be one of the risk factor in 
development of diabetes. So it is reasonable to include vitamin D estimation in 
the diabetic patients. The study also suggests that increased fasting , PP blood 
sugar is associated with decreased vitamin D level. The study also suggest that 
altered lipid profile in Diabetic patients was associated with low vitamin D 
level. 
 
Vitamin D act as a risk factor for type 2 diabetes mellitus development 
and because of its effect on glycemic status and lipid profile, it might affect the 
precipitating risk factors for the onset of prognosis of diabetic complication. 
So, improving the vitamin D level can prevent / delay the development of 
diabetes mellitus and its complication. This goal may be achieved by life style 
modification. 
 
Regular vitamin D screening in high risk patients and vitamin D 
supplementation and fortification of food with Vitamin D is needed to attain 
good glycemic control. 
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 VIII. SCOPE FOR FURTHER STUDY 
 
 

 Studies are needed to confirm the impact of vitamin D on alpha 
cells (glucagon) and islet beta cells . 
 
 Mechanism of vitamin D on insulin resistance has to be 
determined


 Mechanism of vitamin D on metabolic and immune pathways of 
diabetes has to be studied.


 Environmental and genetic mechanism of diabetes and its 
association of vitamin D has to be evaluated.

 Polymorphic studies of vitamin D in diabetes mellitus are needed.
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 IX. LIMITATION OF THE STUDY 
 
 
 Large well designed randomized controlled interventional study 
is needed to clarify the relationship between vitamin D and type 2


diabetes 

 If the sample size was large the findings in the study could have 
been extrapolated to the general population.



 Confounding factors for vitamin D like duration of exposure, 
complexion of skin etc , are not evaluated in this study.



 The relatively small sample size, was not enough to correlate 
serum vitamin D with other factors.



 Prediabetic / impaired diabetes patients were not included in the 
study.

 

 Serum apolipoprotein’s were not estimated. So the relationship 
 
of  these apolipprotein’s with vitamin D  was  not established. 
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 PROFORMA 
 
 
NAME : 
 
AGE/SEX : 
 
DATE : 
 
PRESENT HISORY: 
 
 
 
 
PAST HISTORY: 
 
 
OP NO: 
 
OCCUPATION: 
 
ADDRESS: 
 
The duration of  Diabetes 
 
H/O treatment for  diabetes , dyslipedemia 
 
History of  cardiac / kidney disease. 
 
History of liver disease 
 
History of an  arthritis , malignancy 
 
PERSONAL HOISORY: 
 
 H/O Smoking, Alcohol intake.
 
FAMILY HISTORY : 
 
 H/O Diabetes
 H/O Hypertension
 
 
 
ON EXAMINATION : 
 
GENERAL EXAMINATION: 
 
VITALS: 
 
BP: 
 
CVS: 
 
PER ABDOMEN: 
 
PULSE RATE: 
 
RS: 
 
CNS: 
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 INVESTIGATIONS: 
 
 
1) Vitamin D- 25 HYDROXY CHOLECALCIFEROL 
 
 
2) Fasting, Post prandial blood sugar 
 
 
3) Serum Urea 
 
 
4) Serum creatinine 
 
 
5) HbA1C 
 
 
6) Total cholesterol 
 
 
7) LDL cholesterol 
 
 
8) Triglyceride 
 
 
9) HDL cholesterol 
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 PATIENT CONSENT FORM 
 
 
Study Title: Effect of Serum 25 Hydroxy Cholecalciferol On 
Glycemic Status And Lipid Profile In Type 2 Diabetes Mellitus. 
 
Study centre: govt. Kilpauk medical college hospital, CHENNAI. 
 
PATIENT’S NAME: 
 
 
PATIENT’S AGE: 
 
IDENTIFICATION NUMBER: 
 
 
I confirm that I have understood the purpose and procedure of the above 
study. I have the opportunity to ask any questions and all my questions and 
doubts have been answered to my complete satisfaction. 
 
I understand that my participation in this study is voluntary and that I 
am free to withdraw at any time without giving reason, without my legal rights 
being affected. 
 
I understand that the sponsor of clinical study, working on sponsor’s 
behalf, the ethical committee and the regulatory authorities will not need my 
permission to look at my health records, both in respect of the current study 
and any further research that may be conducted in relation to it, even if I 
withdraw from the study I agree to this access. However I understand that my 
identity would not be revealed in any information released to third parties 
unless as required under the law. I agree not to restrict the use of any data or 
results that arise from the study. 
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 I hereby consent to participate in this study. 
 
 
I hereby give permission to undergo complete clinical examination 
and diagnostic tests including hematological, biochemical tests. 
 
 
 
 
 
 
 
 
Signature of the investigator: Signature/thumb impression 
 
Name of the investigator Patient’s name and address: 
 
 
 
 
 
 
 
 
 
 
 
 
Place: Place: 
 
Date: Date: 
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